Pfizer Animal Health, part of drug behemoth Pfizer, has entered into an agreement to acquire multiple product franchises from fellow USA-based Schering-Plough covering all major animal health species including cattle, swine, equine and companion animals.
Specifically, Pfizer Animal Health will acquire from S-P a number of products for sale in the European Economic Area covering several categories, including vaccines, specialty products, parasiticides and anti-inflammatory products for animals.
The acquisition is subject to certain closing conditions, including antitrust approval. Terms of the agreement were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze